Articles tagged with Pharmacological Inhibitors
A retrospective cohort study found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly reduced the risk of end-stage renal disease, obstructive airway disease, and pneumonia in patients with type 2 diabetes. SGLT2i may be a better alternative to dipeptidyl peptidase-4 inhibitors for extra-glycaemic protection.
A new study by Osaka University researchers demonstrates that the endothelial cell-specific protein Robo4 plays a crucial role in reducing mortality in severe infection. By upregulating Robo4 expression, a drug treatment can decrease vascular permeability and increase survival rates.
Researchers found that MK256 induced differentiation and maturation in leukemia stem cells, inhibiting proliferation of AML cell lines. The study also showed dose-dependent inhibition of the STAT pathway in both in vitro and in vivo studies.
Mandated PDMP use in US states reduced opioid prescriptions by 6.1% but led to a 50.1% increase in heroin-related deaths, according to researchers from the University of Texas at Dallas.
Researchers discovered Empa, an FDA-approved diabetes medication, improved blood vessel function and reduced arterial stiffness in aged male mice. The study suggests SGLT2 inhibition may be a therapeutic tool to delay or reverse vascular aging in humans.
A novel preclinical drug has been developed to inhibit the kinase enzyme Cdk5, which is implicated in neuropsychiatric and neurodegenerative conditions. The drug, 25-106, is brain-permeable and shows promise in altering neurobehavior in mice with anxiety-like behavior.
Biomed Valley Discoveries will present four posters on ulixertinib (BVD-523), a first-in-class ERK1/2 inhibitor, at the AACR Annual Meeting 2022. The presentations focus on ulixertinib's potential in combating acquired resistance to the drug and its efficacy in combination with other therapies.
Vanderbilt researchers discover how a protein may treat schizophrenia, including reversing working memory deficits. Enhancing the activity of mGlu1 selectively increases the activity of specific inhibitory interneurons, restoring their ability to inhibit neuronal circuits.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
Research reveals that inhibiting Mcl-1 protein can induce apoptosis in estrogen receptor-positive breast cancer cells, suggesting a potential therapeutic strategy for this type of cancer. The study also found that combining Mcl-1 inhibition with ABT-263 increased cell death in ER+ breast cancer cells.
PDE5 inhibitors have been approved to treat lower urinary tract symptoms and pulmonary arterial hypertension, with potential benefits in diabetes and cancer treatment due to their blood vessel dilation effects
A new study led by William Kerr of SUNY Upstate Medical University found that SHIP1 inhibition improved metabolic phenotypes in mice fed a high-fat diet. The results showed that SHIP1 inhibition prevented excess weight gain, improved blood sugar control, and reduced inflammation in adipose tissue.
Researchers discovered slow-binding inhibitors (SBIs) with high selectivity, long target-residence times, and minimal side effects for treating Alzheimer's disease, myasthenia, and neuroprotection. SBIs also have toxicological importance, playing a role in mechanisms of resistance against irreversible agents.
University of Texas Medical Branch researchers have identified a protein called Epac1 that blocks leptin's activity in the brain. Blocking this protein can increase leptin sensitivity and lead to lower body weight, body fat percentage, blood plasma leptin levels, and improved glucose tolerance.
A recent study reverses many Fragile X syndrome symptoms in adult mice using a new compound CTEP. The study found that pharmacologic inhibition of mGlu5 receptor can correct FXS symptoms, including learning and memory deficits and auditory hypersensitivity.
A University of Pennsylvania study suggests that taking ibuprofen before aspirin can inhibit the cardioprotective benefits gained from a daily aspirin regimen. The study found no competitive interaction between aspirin and Tylenol or Vioxx when taken separately.
Researchers at UT Southwestern Medical Center designed and tested synthetic inhibitors against telomerase, a key enzyme in cancer cell immortality. These inhibitors successfully caused progressive telomere shortening and cell death in human breast and prostate cancer cells.
Researchers at Thomas Jefferson University and Oxford University have found a promising drug against the hepatitis C virus (HCV), called N-nonyl-DNJ, which inhibits the activity of an important cellular enzyme, glucosidase. This drug may sidestep resistant viruses, a major problem with current treatments.
Researchers found that COX-2 inhibitors suppress prostacyclin, a hormone-like substance produced in blood vessels, which can lead to increased thrombosis risk. This discovery raises concerns about the potential cardiovascular risks of these new pain relievers.
A study by Jane E. Freedman found that purple grape juice inhibits platelet aggregation, reducing blood clotting risk and improving cardiovascular health. The flavonoid quercetin was also shown to have antioxidant properties, preventing the inactivation of nitric oxide.
Researchers at Washington University School of Medicine have shown that a compound called BAF protects newborn rats from brain damage. The findings suggest that administering BAF after the damaging procedure is just as effective as giving it ahead of time, and that it also protects when injected systemically.
Researchers at Jefferson Medical College have found a way to inhibit the hepatitis B virus by blocking its envelope creation, resulting in a dramatic drop in viral levels. The discovery may provide new leads for treating chronic HBV and HCV infections in humans.
Researchers have made rapid progress on a new class of anti-cancer drugs that target the Ras protein activation pathway, which causes up to 90% of pancreatic cancers. Laboratory studies have shown effective inhibition of cancer cells using FTase inhibitors.